强生公司获得FDA认可集成导管消融解决方案

2026-07-08 20:41

Johnson & Johnson (JNJ) on Wednesday announced the FDA approval for a MedTech device designed to deliver both radiofrequency and pulsed field energy in a single integrated catheter for cardiac ablation procedures.
The product, branded as the Dual Energy THERMOCOOL SMARTTOUCH SF Platform, is intended to help electrophysiologists handle complex cases depending on the patient's anatomy, the company said.
The catheter solution is integrated with J&J’s (JNJ) CARTO ecosystem, a three-dimensional electroanatomical mapping platform. The company expects to begin a phased launch of the DE STSF Platform in the U.S. with the first commercial procedures set to begin this summer.
“Following a successful introduction in Europe, we’re pleased to rapidly expand access to this technology in the U.S.,” said Michael Bodner, company group chair of electrophysiology & neurovascular at J&J’s (JNJ) MedTech division.

More on Johnson & Johnson